{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:37:31Z","timestamp":1722929851135},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The management of recurrent\/refractory (R\/R) Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) remains challenging. Previously published data have shown some efficacy of rituximab in this setting. The purpose of this phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial was to investigate the activity of ofatumumab in combination with etoposide, steroids, cytarabine and cisplatin (O\u2010<jats:styled-content style=\"fixed-case\">ESHAP<\/jats:styled-content>) in 62 patients with R\/R classical <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>. Treatment consisted of <jats:styled-content style=\"fixed-case\">ESHAP<\/jats:styled-content> plus ofatumumab 1000\u00a0mg on days 1 and 8 of the first cycle and day 1 of the second and third cycles. O\u2010<jats:styled-content style=\"fixed-case\">ESHAP<\/jats:styled-content> was well tolerated with only 3% of patients requiring treatment discontinuation because of adverse events. Overall response rate was 73% (44% complete metabolic response). In multivariate analysis, early relapse (<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0\u00b7001), bulky disease (<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0\u00b7001) and B symptoms (<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0\u00b7001) were the most important prognostic factors for response. No failures of stem cell mobilization were observed. The high response rate, particularly the complete metabolic response rate, the low toxicity profile, and the high mobilizing potential of the O\u2010<jats:styled-content style=\"fixed-case\">ESHAP<\/jats:styled-content> regimen suggest that patients with R\/R <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> may benefit from this salvage regimen. However, with the encouraging results observed with other new therapeutic agents in <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>, the O\u2010<jats:styled-content style=\"fixed-case\">ESHAP<\/jats:styled-content> regimen could be restricted to patients failing these agents or to those with R\/R nodular lymphocyte\u2010predominant <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14133","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T07:27:48Z","timestamp":1463470068000},"page":"859-867","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase <scp>II<\/scp> trial of ofatumumab plus <scp>ESHAP<\/scp> (O\u2010<scp>ESHAP<\/scp>) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first\u2010line chemotherapy"],"prefix":"10.1111","volume":"174","author":[{"given":"Carmen","family":"Mart\u00ednez","sequence":"first","affiliation":[{"name":"Department of Haematology Hospital Cl\u00ednic of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u00edaz\u2010L\u00f3pez","sequence":"additional","affiliation":[{"name":"Pathology Department MD Anderson Cancer Centre Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Rodriguez\u2010Calvillo","sequence":"additional","affiliation":[{"name":"Department of Haematology Complejo Hospitalario de Navarra Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda\u2010Sanz","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Cl\u00ednico of Salamanca Salamanca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Terol","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Cl\u00ednico of Valencia Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"P\u00e9rez\u2010Ceballos","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Morales Messeguer of Murcia Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Germans Trias i Pujol of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cantalapiedra","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital R\u00edo Hortega of Valladolid Valladolid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Domingo\u2010Domenech","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Duran i Reynals of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Universitario de Canarias Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Universitari Son Espases of Mallorca Palma Mallorca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Espeso","sequence":"additional","affiliation":[{"name":"Department of Haematology Complejo Hospitalario Carlos Haya of M\u00e1laga Malaga Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco\u2010Javier","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Ram\u00f3n y Cajal of Madrid Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital de la Santa Creu i Sant Pau of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan F.","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pathology Department MD Anderson Cancer Centre Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Department of Haematology Hospital Duran i Reynals of Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026454831340"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.500.500","article-title":"Addition of rituximab to BEACOPPescalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study","volume":"124","author":"Borchmann P.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10164"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2014"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.396"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.321"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-362475"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.2.467"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp487"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.582.582","article-title":"Evaluation of the r\u00e9gimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I\u2010II trial from the Spanish Group of lymphoma and bone marrow transplantation (GELTAMO)","volume":"126","author":"Garc\u00eda\u2010Sanz R.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21664"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf221"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-402792"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31816d1d6a"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-288373"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2114-0"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce A.S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282756"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23237"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.019943"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1278"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10661"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1395"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11511"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405456"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14133","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:01:25Z","timestamp":1696291285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/bjh.14133"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14133","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2016,5,17]]},"assertion":[{"value":"2015-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}